Work

A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps3091

Authors: Martin Wermke, Helmuth Schmidt, Hildegard Nolte, Sebastian Ochsenreither, Jonathan Back, Yacine Salhi, Eliel Bayever

Institutions: University Hospital Carl Gustav Carus, Technische Universität Dresden, Johannes Gutenberg University Mainz, Stiftung Charité, Charité – Universitätsmedizin Berlin, Glenmark Pharmaceuticals (Switzerland), Merrimack Pharmaceuticals (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2762299698

Cites:

Cited by: 6

Related to: 10